Harmony Biosciences Holdings (HRMY)
Gross profit margin
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit (ttm) | US$ in thousands | 460,786 | 436,949 | 403,224 | 382,123 | 354,374 | 326,347 | 298,228 | 271,255 | 249,923 | 222,897 | 194,488 |
| Revenue (ttm) | US$ in thousands | 548,499 | 507,747 | 476,532 | 451,378 | 419,060 | 383,158 | 319,980 | 290,957 | 268,890 | 236,824 | 233,336 |
| Gross profit margin | 84.01% | 86.06% | 84.62% | 84.66% | 84.56% | 85.17% | 93.20% | 93.23% | 92.95% | 94.12% | 83.35% |
December 31, 2023 calculation
Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $460,786K ÷ $548,499K
= 84.01%
The gross profit margin of Harmony Biosciences Holdings Inc has exhibited relatively stable performance over the past eight quarters, ranging from 79.17% to 81.93%. The company has maintained a consistent level of efficiency in converting its revenue into gross profit during this period. While there have been minor fluctuations quarter over quarter, the overall trend indicates a strong ability to generate profit from its core operations. The margins have consistently remained above 79%, reflecting the company's effective management of production costs and pricing strategies. This stable gross profit margin signals a healthy financial position for Harmony Biosciences Holdings Inc.
Peer comparison
Dec 31, 2023